Brahmam Pujala

This inventor holds 22 USPTO granted patents and 29 published patent applications, plus 1 CIPO patent and 2 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Medivation Technologies, Inc., Nuvation Bio Inc., Praxis Biotech LLC. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Brahmam Pujala. Retrieved from https://idiyas.com/inventor/brahmam-pujala

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 22 (Patent Applications = 29)

% Patents Active = 68.2

CIPO Patents = 1 (Patent Applications = 9)

EPO Patents = 2 (Patent Applications = 18)

Average Co-Inventor Count = 7.9

ph-index = 3

Forward Citations = 24(Granted Patents)

Location History:

Uttar Pradesh, IN (2022)
Noida, IN (2017 - 2023)
Greater Noida, IN (2020 - 2023)

Company Filing History:

6 out of 63

Medivation Technologies, Inc.

Oregon State University

patents

Years Active: 2017-2026

Loading Chart...

Areas of Expertise:

ATF6 Modulators

Aryl Hydrocarbon Receptor

ENPP1 Inhibitors

Fibroblast Activation Protein

Wee1 Inhibitors

Integrated Stress Response

Heterocyclic Compounds

Kinase Inhibitors

Pyrrole Compounds

Pyrazole Compounds

Diarylhydantoin Compounds

Compounds and Methods

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12662478 - ATF6 MODULATORS AND USES THEREOF (2026-06-23),

2. 12473262 - Aryl hydrocarbon receptor activators (2025-11-18),

3. 12325720 - Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof (2025-06-10),

4. 12325702 - ATF6 inhibitors and uses thereof (2025-06-10),

5. 11780821 - Inhibitors of fibroblast activation protein (2023-10-10),

6. 11702401 - Compounds and methods of use (2023-07-18),

7. 11504364 - Inhibitors of fibroblast activation protein (2022-11-22),

8. 11332473 - Substituted pyrazolo[3,4-d]pyrimidines as Wee1 inhibitors (2022-05-17),

9. 11318133 - Modulators of integrated stress response pathway (2022-05-03),

10. 11299493 - Heterocyclic compounds and uses thereof (2022-04-12),

11. 11292782 - Diarylhydantoin compounds and methods of use thereof (2022-04-05),

12. 11230542 - Inhibitors of integrated stress response pathway (2022-01-25),

13. 11174252 - Heterocyclic compounds as kinase inhibitors (2021-11-16),

14. 11166942 - Inhibitors of integrated stress response pathway (2021-11-09),

15. 11053216 - Compounds and methods of use (2021-07-06),

Title: Brahmam Pujala: Innovator in Pharmaceutical Patents

Introduction

Brahmam Pujala is an esteemed inventor located in Greater Noida, India, renowned for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 20 patents, he has made vital strides in developing novel therapies aimed at treating various medical conditions.

Latest Patents

Among his latest innovations are two notable patents:

1. **Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof** - This invention discloses compounds that are useful in treating conditions associated with dysfunction of the ENPP1 enzyme. Specifically, it introduces a compound of formula (J), which exhibits inhibitory activity against ENPP1. The patent outlines a method for treating conditions linked to the over-expression of the ENPP1 gene using such compounds, including their pharmaceutical compositions and kits.

2. **ATF6 inhibitors and uses thereof** - This patent describes compounds that serve as inhibitors of Activating Transcription Factor 6 (ATF6). These compounds may be utilized as therapeutic agents in treating diseases mediated by ATF6, with particular applications in viral infections, neurodegenerative diseases, vascular diseases, and cancer.

Career Highlights

Brahmam Pujala's career includes significant positions at reputable companies such as Nuvation Bio Inc. and Medivation Technologies, Inc. His work at these organizations has contributed to advancing research and development in innovative drug therapies.

Collaborations

Throughout his career, he has collaborated with notable professionals, including Sarvajit Chakravarty and Son Minh Pham. These collaborations have facilitated the exchange of ideas and fostered advancements in the field of pharmaceutical sciences.

Conclusion

With a strong foundation in pharmaceutical innovations and a growing list of patents, Brahmam Pujala continues to be a trailblazer in developing effective treatments for various diseases. His ongoing contributions underscore the importance of innovative solutions in addressing today's healthcare challenges.

Profile summary based on public USPTO records.